Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data

Search results

• Fox Chase Cancer Center: Avapritinib Provided Greater Benefit Than Other Tyrosine Kinase Inhibitors for Mutated Gastrointestinal Stromal Tumors

  von Mehren, M.

  05/18/21 → 05/19/21

  2 items of Media coverage

  Press/Media